Welcome to our dedicated page for Gritstone bio news (Ticker: GRTS), a resource for investors and traders seeking the latest updates and insights on Gritstone bio stock.
Gritstone bio, Inc. (Nasdaq: GRTS) is at the forefront of developing personalized cancer immunotherapies and next-generation vaccines for infectious diseases. Headquartered in Emeryville, California, with additional key functions in Cambridge, Massachusetts, Gritstone is a clinical-stage biotechnology company leveraging innovative vectors and payloads to train the immune system to combat critical disease targets. Founded in 2015 with a strong financial backing of $102 million in Series A financing, Gritstone brings together a distinguished team of scientific founders, an experienced management team, and a successful board of directors.
Gritstone's pipeline includes multiple product candidates targeting solid tumors and viral diseases. Their key programs include GRANITE, a personalized neoantigen vaccine program, and SLATE, an 'off-the-shelf' neoantigen vaccine program. Additionally, they are developing CORAL, a next-generation SARS-CoV-2 vaccine designed to drive both B cell and T cell immunity using self-amplifying mRNA (samRNA). Gritstone's collaboration with the National Cancer Institute (NCI) and other industry leaders underscores the pioneering vision and scientific rigor that guides their innovative approaches.
Recent clinical updates have highlighted promising preliminary Phase 2 data for GRANITE in metastatic colorectal cancer (MSS-CRC), showing a progression-free survival benefit. SLATE-KRAS, a variant of their 'off-the-shelf' neoantigen vaccine, has also demonstrated superior immunogenicity in Phase 2 studies. Additionally, their CORAL program continues to show robust and durable immune responses in diverse populations, including those living with HIV.
Gritstone's financial condition remains strong, bolstered by recent public offerings and continued support from prominent foundations and government agencies. Their latest corporate developments and financial results reflect a clear trajectory towards advancing their clinical programs and achieving regulatory milestones.
Gritstone bio, Inc. (Nasdaq: GRTS) appointed Stephen Webster, a finance executive with 30 years of experience, to its Board of Directors. Webster's expertise in raising capital and business development will be important as the company prepares for Phase 2 GRANITE data and potential growth. Steve Krognes will not stand for re-election at the 2024 Annual Meeting.
FAQ
What is the current stock price of Gritstone bio (GRTS)?
What is the market cap of Gritstone bio (GRTS)?
What does Gritstone bio, Inc. specialize in?
Where is Gritstone bio, Inc. headquartered?
What are Gritstone's key product candidates?
What recent clinical updates has Gritstone reported?
Who are Gritstone bio's collaborators?
When was Gritstone bio founded, and how was it funded?
What makes Gritstone's vaccines unique?
How does Gritstone's financial condition look?
What is the significance of the CORAL program?
What is the future outlook for Gritstone bio?
